GlassScriptPhysician profile
Heather M Macadam
NPI 1265411052
$5,625.88
in general payments reported to CMS, 2019-2025
36 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $377 · 2021: $339 · 2022: $819 · 2023: $1,011 · 2024: $806 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,066.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,057.36 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $617.97 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $588.99 | 2019-2025 | |
| Abbvie INC. | $445.32 | 2021-2025 | |
| Amarin Pharma, INC. | $229.72 | 2019-2022 | |
| Amgen INC. | $172.67 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.87 | 2019-2023 | Spiriva Respimat, Tradjenta, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $120.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.65 | 2019-2022 | |
| Indivior INC. | $99.95 | 2019-2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.66 | 2019-2020 | |
| Astellas Pharma US INC | $89.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $60.82 | 2019-2023 | Xarelto |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Macadam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.